Identification of ATRNL1 and WNT9A as novel key genes and drug candidates in hypertrophic cardiomyopathy: integrative bioinformatics and experimental validation
We identified several novel genes in HCM development, among which <i>ATRNL1</i> and <i>WNT9A</i> were validated by cell and animal models. A deficiency of hsa-miR-1469 may be a mechanism behind HCM development. Novel medications for HCM treatment include propylthiouracil and triptolide.
Authors
- Hao Qin (ORCID: https://orcid.org/0000-0002-9941-1701)
- Yanhui Liao (ORCID: https://orcid.org/0000-0003-4735-3252)
- Longlong Hu (ORCID: https://orcid.org/0000-0002-3099-2130)
- Yang Chen (ORCID: https://orcid.org/0000-0001-9406-8273)
- Renqiang Yang (ORCID: https://orcid.org/0000-0002-9064-7822)
- Shucai Xiao (ORCID: https://orcid.org/0009-0004-9688-015X)
- Huabin He
- Huijian Wang
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Second Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2024-09-12
- DOI
- https://doi.org/10.3389/fmolb.2024.1458434
- Citations
- 2
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.80